These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 20235353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S, Schiller B.
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [Abstract] [Full Text] [Related]

  • 4. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H, Schiffl H, Lederer SR.
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK.
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Erythropoesis-stimulating agents: past, present and future].
    Kes P, Basić-Jukić N.
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [Abstract] [Full Text] [Related]

  • 9. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE, Szczech LA.
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
    Agarwal AK, Singh AK.
    Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N.
    Med Klin (Munich); 2008 Sep 15; 103(9):633-7. PubMed ID: 18813886
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A.
    Blood Purif; 2010 Sep 15; 29(1):1-12. PubMed ID: 19816014
    [Abstract] [Full Text] [Related]

  • 20. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK, Hertello P.
    Nephrol Nurs J; 2005 Sep 15; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.